A high frequent BRCA1 founder mutation identified in the Greenlandic population
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A high frequent BRCA1 founder mutation identified in the Greenlandic population. / Harboe, Theresa Larriba; Eiberg, Hans; Kern, Peder; Ejlertsen, Bent; Nedergaard, Lotte; Timmermans-Wielenga, Vera; Nielsen, Inge-Merete; Bisgaard, Marie Luise.
In: Familial Cancer, Vol. 8, No. 4, 2009, p. 413-9.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A high frequent BRCA1 founder mutation identified in the Greenlandic population
AU - Harboe, Theresa Larriba
AU - Eiberg, Hans
AU - Kern, Peder
AU - Ejlertsen, Bent
AU - Nedergaard, Lotte
AU - Timmermans-Wielenga, Vera
AU - Nielsen, Inge-Merete
AU - Bisgaard, Marie Luise
PY - 2009
Y1 - 2009
N2 - Approximately 10% of all breast and ovarian cancers are dominantly inherited and mutations are mainly found in the BRCA 1 and 2 genes. The penetrance of BRCA1 mutations is reported to be between 68 and 92% and confers a 36-92% life time risk of breast cancer. Most mutations in BRCA1 are uniquely occurring mutations, but founder mutations have been described. In this study we describe a founder mutation with wide spread presence in the Inuit population. We have screened 2,869 persons from Greenland for the presence of a BRCA1 mutation (p.Cys39Gly) only found in the Inuit population. The overall carrier frequency was 1.6% in the general population, but the frequency differs geographically from 0.6% on the West coast to 9.7% in the previously isolated population of the East coast. This is to our knowledge the highest population frequency of a BRCA1 mutation ever to be described. To determine the clinical relevance of the mutation, we have examined ten breast cancer patients and nine ovarian cancer patients from Greenland for the presence of the p.Cys39Gly mutation. We found three ovarian cancer patients (33%) and one breast cancer patient (10%) carrying the mutation. The high number of women carrying a BRCA1 mutation known to trigger the development of potentially lethal diseases leads us to recommend an offer of genetic counselling and test for the mutation to all females of Inuit origin, thereby hopefully preventing a number of breast and ovarian cancer deaths.
AB - Approximately 10% of all breast and ovarian cancers are dominantly inherited and mutations are mainly found in the BRCA 1 and 2 genes. The penetrance of BRCA1 mutations is reported to be between 68 and 92% and confers a 36-92% life time risk of breast cancer. Most mutations in BRCA1 are uniquely occurring mutations, but founder mutations have been described. In this study we describe a founder mutation with wide spread presence in the Inuit population. We have screened 2,869 persons from Greenland for the presence of a BRCA1 mutation (p.Cys39Gly) only found in the Inuit population. The overall carrier frequency was 1.6% in the general population, but the frequency differs geographically from 0.6% on the West coast to 9.7% in the previously isolated population of the East coast. This is to our knowledge the highest population frequency of a BRCA1 mutation ever to be described. To determine the clinical relevance of the mutation, we have examined ten breast cancer patients and nine ovarian cancer patients from Greenland for the presence of the p.Cys39Gly mutation. We found three ovarian cancer patients (33%) and one breast cancer patient (10%) carrying the mutation. The high number of women carrying a BRCA1 mutation known to trigger the development of potentially lethal diseases leads us to recommend an offer of genetic counselling and test for the mutation to all females of Inuit origin, thereby hopefully preventing a number of breast and ovarian cancer deaths.
U2 - 10.1007/s10689-009-9257-5
DO - 10.1007/s10689-009-9257-5
M3 - Journal article
C2 - 19504351
VL - 8
SP - 413
EP - 419
JO - Familial Cancer
JF - Familial Cancer
SN - 1389-9600
IS - 4
ER -
ID: 15790399